KDR and pancreatic neoplasm: Moreover, in combination therapy of peptide for VEGFR2 with gemcitabine for patients with metastatic and unresectable pancreatic cancer, the median overall survival time of all 18 patients who completed at least one course of the treatment was 8.7 months.